{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:51:51Z","timestamp":1788274311873,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of &amp;lt;2\u2009years. Especially, most BPDCN patients present with extensive and non-specific skin lesions, usually leading to misdiagnosis as a skin disease and delay therapy. As for treatment, most patients with BPDCN experience relapse shortly after treatment with the traditional regimens. The alleviation of skin symptoms reflects the effects of clinical treatments. Herein, we report a case of a 71-year-old man with intermittent and gradually expanding skin lesions over his chest, abdomen, and back for 1\u2009year. On admission, physical examination revealed extensive skin lesions and multiple enlarged lymph nodes. Laboratory examinations showed pancytopenia and numerous malignant cells in the peripheral blood smear (60%), bone marrow aspirate smear (73.5%). Immunophenotyping using flow cytometry and immunohistochemistry presented large numbers of BPDCN cells in the bone marrow, cervical lymph nodes and dermal tissue. PET\/CT revealed multiple enlarged lymph nodes and splenomegaly. Once the diagnosis was identified as BPDCN, the patient began treatment with the oral BCL2 inhibitor venetoclax and subcutaneously administered azacitidine. After the first course, skin lesions reduced markedly and complete remission was achieved in the bone marrow. Our study and current cumulative data according to reviewing systematically suggest that venetoclax combined with azacitidine is safe, effective, and applicable in the treatment of BPDCN, especially for elderly relapsed\/refractory patients. This study, therefore, significantly contributes to the literature on the current and future treatment for BPDCN.<\/jats:p>","DOI":"10.3389\/fmed.2024.1425833","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:42:37Z","timestamp":1721176957000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaoning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.clml.2019.06.002","article-title":"Blastic Plasmacytoid dendritic cell neoplasm-current insights","volume":"19","author":"Venugopal","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.v99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard","year":"2002","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.leukres.2011.07.033","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review","volume":"36","author":"Rauh","year":"2012","journal-title":"Leuk Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/PAP.0b013e3181bb6bc2","article-title":"Plasmacytoid dendritic cells: physiologic roles and pathologic states","volume":"16","author":"Jegalian","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17474086.2021.1988848","article-title":"Targeting CD123 in BPDCN: an emerging field","volume":"14","author":"DiPippo","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/leu.2014.64","article-title":"Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition","volume":"28","author":"Sapienza","year":"2014","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1080\/10428194.2022.2042685","article-title":"Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm","volume":"63","author":"D\u00edaz Acedo","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American Blastic Plasmacytoid dendritic cell neoplasm consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.hoc.2019.10.005","article-title":"Prospects for Venetoclax in myelodysplastic syndromes","volume":"34","author":"Garcia","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","article-title":"Practical Management of the Venetoclax-Treated Patient in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"13","author":"Waggoner","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic Plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ajh.2830470406","article-title":"High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma","volume":"47","author":"Adachi","year":"1994","journal-title":"Am J Hematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","article-title":"Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications","volume":"95","author":"Jegalian","year":"2010","journal-title":"Haematologica"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"106199","DOI":"10.1016\/j.leukres.2019.106199","article-title":"Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: a case-report and review of literature","volume":"85","author":"Beziat","year":"2019","journal-title":"Leuk Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00277-020-03939-1","article-title":"Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm","volume":"99","author":"Piccini","year":"2020","journal-title":"Ann Hematol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3324\/haematol.2018.202093","article-title":"Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target","volume":"104","author":"Sapienza","year":"2019","journal-title":"Haematologica"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3109\/10428194.2016.1160084","article-title":"Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases","volume":"57","author":"Khwaja","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/ejh.12294","article-title":"Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine","volume":"93","author":"Laribi","year":"2014","journal-title":"Eur J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am J Hematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e230332","DOI":"10.1136\/bcr-2019-230332","article-title":"Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia","volume":"12","author":"Khan","year":"2019","journal-title":"BMJ Case Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00277-021-04718-2","article-title":"Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm","volume":"101","author":"Le Calloch","year":"2022","journal-title":"Ann Hematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1080\/10428194.2021.1941938","article-title":"Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) \u2013 a new perspective","volume":"62","author":"Mirgh","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1177\/1078155220951850","article-title":"Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review","volume":"27","author":"Samhouri","year":"2021","journal-title":"J Oncol Pharm Pract"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1425833\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:42:41Z","timestamp":1721176961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1425833\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":30,"alternative-id":["10.3389\/fmed.2024.1425833"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1425833","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"article-number":"1425833"}}